GMM Pfaudler Shares Jump 14% After Q1 FY27 Profit Nearly Doubles

Spread love

By S. JHA

The counter touched a fresh high for the session on heavy volumes a day after the company reported a 118% jump in quarterly profit and unveiled a four-division restructuring.

Mumbai, August 6, 2026 — Shares of GMM Pfaudler Limited surged as much as 14% on the BSE on Thursday, extending a sharp post-earnings rally a day after the glass-lined equipment maker reported a near-doubling of quarterly profit for the first quarter of FY27.

The stock opened at ₹869.00 against a previous close of ₹857.20, then rallied through the session to an intraday high of ₹1,028.00 — just shy of its upper price band of ₹1,028.60 under the 20% circuit filter — before easing to trade with gains near 14%.

The stock’s low for the day was ₹852.35, and the volume-weighted average price stood at ₹972.87, according to BSE data. Total traded quantity came in at 2.26 lakh shares for a turnover of ₹21.98 crore, against a two-week average quantity of 4,756 shares, pointing to a sharp pickup in trading interest around the counter.

At the day’s high, the stock remained well below its 52-week high of ₹1,344.10 hit earlier in the year, but comfortably clear of its 52-week low of ₹735.35 touched during the stock’s extended slide over the past year.

GMM Pfaudler’s full market capitalisation stood at ₹4,425.59 crore, with free-float market cap at ₹3,294.39 crore.

Why Restaurant Brands Asia Shares Surged Nearly 20% Today

What Triggered the Rally

The move follows GMM Pfaudler’s board approving unaudited consolidated results for the June 2026 quarter on August 5, ahead of a scheduled earnings call on August 6. The company reported consolidated revenue of ₹924.76 crore for Q1 FY27, up 16% year-on-year, while profit attributable to equity holders came in at ₹23.90 crore, more than double the year-ago figure.

Profit for the period, before minority interests, was ₹22.10 crore — a 118% jump from the same quarter last year and a 44% sequential increase, according to the company’s exchange filing. Order intake for the quarter stood at ₹1,007 crore, up 16% sequentially, taking the order backlog to ₹2,289 crore, up 20% year-on-year.

Managing Director Tarak Patel attributed the performance to the company’s diversified portfolio, saying revenue growth for the quarter reflected the strength of its business mix and execution capabilities, even as EBITDA came in lower than the year-ago period due to cost pressures in the international business.

Alongside the results, the company announced a reorganisation of its operations into four distinct global business divisions, a move it said was intended to sharpen strategic focus and drive cost efficiencies across regions. Management also flagged plans to repay approximately €7 million of debt during the September quarter, funded through internal accruals, and said it would move to an annual dividend payout cycle instead of the current semi-annual schedule, without changing its underlying dividend policy.

The Bigger Picture

Thursday’s rally marks a sharp reversal for a stock that has been under pressure for much of the past year. GMM Pfaudler shares were down more than 36% over the preceding twelve months as of late June, weighed by a prolonged slowdown in Europe’s chemical and specialty chemical markets, where the company has significant exposure through its German operations, alongside restructuring costs tied to a UK facility closure and cost right-sizing in Germany.

The stock’s 52-week trading range of ₹735.35 to ₹1,344.10 reflects that volatility.

Even after Thursday’s move, the stock trades at a meaningful discount to its 52-week high. On a trailing basis, the counter carries a standalone P/E of 82.31 and a consolidated P/E of 65.15, against standalone and consolidated EPS (TTM) of ₹11.96 and ₹15.11 respectively — valuations that remain elevated relative to some process-equipment peers, reflecting the market’s bet on a sustained earnings recovery through FY27. Return on equity stood at 7.05% with a price-to-book ratio of 5.80.

Sell-side commentary ahead of the results had flagged India’s domestic pharmaceutical and specialty chemicals demand as the key offset to European weakness, with analysts noting that a resolution of margin drag from the international business — aided by the ramp-up of a new low-cost manufacturing hub in Poland — was the main catalyst investors were watching for heading into the print.

Consensus 12-month price targets compiled ahead of the results had clustered in a wide range, with some brokerages pegging fair value near ₹970 based on an FY27 earnings-recovery thesis, while more bullish estimates on aggregator platforms ran considerably higher.

(This is a market update based on exchange data and company disclosures, not investment advice. Readers should consult a registered financial advisor before making investment decisions.)